BioSpace News Archive

The widely available diabetes drug metformin reduced serious COVID outcomes by more than half if started within 4 days of symptoms, in a large, double-blind, randomized, controlled trial conducted by the University of Minnesota and published Aug. 18 in the New England Journal of Medicine, according to the Parsemus Foundation.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended June 30, 2022 and provided an update on upcoming milestones.

InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, announced that it will host a virtual R&D Day on Monday, September 19, 2022, from 10:00 AM to 12:30 PM Eastern Time.

Personalis, Inc. announced that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Personalis Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.

IN8bio, Inc., a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, announced the presentations it will be making at investor and scientific conferences in September 2022.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), today announced that it will host an R&D Day featuring clinical data presentations on ALPN-303, a potentially best-in-class dual B cell cytokine antagonist being developed for the treatment of B cell mediated inflammatory and autoimmune diseases, and davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor in development for the treatment of cancer.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time.

The global HIV/AIDS immunoassay diagnostics market is expected to expand from ~US$ 570 Mn in 2021 to a value of ~US$ 870 Mn by 2030.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the six months ended June 30, 2022 and provided corporate updates.